Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib + Erlotinib in EGFRm+ Advanced NSCLC
NCT02495233Phase 2Terminated
- Sponsor
- Astellas Pharma
- Start
- Sep 2015
- Primary completion
- Sep 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of gilteritinib in non-small cell lung cancer (NSCLC), sponsored by Astellas Pharma. Started Sep 2015; status: terminated.
02
Drugs
gilteritinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02495233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02495233.